We are live on ! Find out more
IMNM icon

Immunome

115 hedge funds and large institutions have $755M invested in Immunome in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 27

31% more capital invested

Capital invested by funds: $578M → $755M (+$177M)

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

6.31% more ownership

Funds ownership: 79.67%85.98% (+6.3%)

2% more funds holding

Funds holding: 113115 (+2)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

83% less call options, than puts

Call options by funds: $4.72M | Put options by funds: $28.3M

Holders
115
Holders Change
+2
Holders Change %
+1.77%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
21
Increased
46
Reduced
27
Closed
18
Calls
$4.72M
Puts
$28.3M
Net Calls
-$23.5M
Net Calls Change
-$23.8M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
126
Aquatic Capital Management
Illinois
-$368K -30,400 Closed
Walleye Capital
127
Walleye Capital
New York
-$308K -25,457 Closed
Voloridge Investment Management
128
Voloridge Investment Management
Florida
-$245K -20,282 Closed
CSS
129
Cubist Systematic Strategies
Connecticut
-$235K -19,421 Closed
FIA
130
FNY Investment Advisers
New York
-$58K -4,860 Closed
Citadel Advisors
131
Citadel Advisors
Florida
-$59.2K -4,167 Closed
Pacer Advisors
132
Pacer Advisors
Pennsylvania
-$7.99K -660 Closed
Carson Wealth (CWM LLC)
133
Carson Wealth (CWM LLC)
Nebraska
+$171 +12 +120%

IMNM Hedge Fund Activity: Q3 2024 in Review

115 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q3 2024, worth a combined $755M — up 31% from $578M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new IMNM positions and 18 closed out — a net gain of 3 holders — while 46 added to existing stakes and 27 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $26.8M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $12.1M sold.

  • 115 institutional investors held Immunome (IMNM) as of Q3 2024, up from 113 in Q2 2024.
  • Funds reported $755M of Immunome stock for Q3 2024, up 31% quarter-over-quarter.
  • 21 funds opened new Immunome positions in Q3 2024 and 18 closed out, a net change of +3 holders.
  • The largest Immunome buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $26.8M added.
  • The largest Immunome seller in Q3 2024 was Vestal Point Capital, an estimated $12.1M sold.

Based on aggregated 13F filings for Q3 2024.